Skip to main content

Life Sciences is now live. See how →

Patent Examiner John S. Kenyon

Art Unit 1625 · Heterocyclic Drug Compounds & Medicinal Chemistry · Tech Center 1600 · 378 applications filed 2021–2026

⚑ Hard · harder than 75% of examiners● Free examiner data

John S. Kenyon is a USPTO patent examiner in Art Unit 1625 (Heterocyclic Drug Compounds & Medicinal Chemistry) with 378 applications from filing years 2021–2026. Examiner Kenyon's allowance rate is 68.4%, below the 82.2% USPTO average for applications filed in the same years. The examiner ranks harder than 75% of examiners. In 2021, decided applications with an examiner interview were allowed 29.1 percentage points more often than those without.

Data through November 2026 from USPTO Patent Center (formerly PAIR) · Methodology

Overview

Free
Difficulty · Hard
harder than 75% of examiners
Easier75th percentileHarder
Allowance rate vs peers
Examiner Kenyon68.4%
Art Unit 162569.9%
USPTO average82.2%
Allowance rate
68.4%
▼ USPTO avg 82.2%
Applications
378
filing years 2021–2026
First-action allowance
14.1%
patented with no rejection
Abandoned
22.5%
share of applications
Avg office actions
0.9
USPTO avg 1.3
Days to first OA
778
▲ USPTO 624
RCE rate
6.6%
USPTO 20.1%
Interview rate
6.6%
USPTO 27.8%

Examiner details

  • Art unit1625 · Heterocyclic Drug Compounds & Medicinal Chemistry
  • Title / gradePrimary Patent Examiner · GS-14
  • Service14 years
  • PhoneOn each office action
  • Email[email protected]
  • In USPTO recordsKENYON, JOHN S
Full signatory authority

Examiner Kenyon can allow an application without a supervisory sign-off.

Examines (USPC classes)
514 · Drug, Bio-Affecting & Body Treating Compositions544 · Organic Compounds (Class 532-570 Series)549 · Organic Compounds (Class 532-570 Series)

How to improve your odds with Examiner Kenyon

  • The data favors an interview. Interviewed cases were allowed more often in both measured years, by 29.1 to 32.6 points.
  • Plan for the timeline. First office action averages 778 days vs the 624-day USPTO norm.
  • Expect a §112. Definiteness & disclosure is the most-issued rejection (134), and applicants overcame it 79.0% of the time.
  • The data favors an RCE here. Cases with an RCE were allowed more often in both measured years, by 9.6 to 34.1 points.

Historical patterns from this examiner's past cases, shown for general information. This is not legal advice and does not predict the outcome of any specific application. Decisions about interviews, RCEs, and claim strategy should be made with a licensed patent attorney or agent.

Rejection patterns & how they get overcome

Free
§101 Eligibility14 issued · 76.9% overcome
§102 Novelty72 issued · 69.0% overcome
§103 Obviousness34 issued · 82.8% overcome
§112 Definiteness & disclosure134 issued · 79.0% overcome
How applicants traverse §112 rejections🔒 Members

Of the 55 winning responses to Examiner Kenyon's §112 rejections that Boundly has classified, 29 (53%) amended the claims and argued, 25 amended without arguing, and 1 argued without amending. Each winning response, with its arguments and claim amendments, is in the file wrapper.

Read the winning §112 argumentsFull REMARKS, amendments, claim trees & redlines from the file wrappers
Start free

Just got an office action from Examiner Kenyon?

Draft your response with Examiner Kenyon's record and Art Unit 1625's history in view, including the rejection patterns, the interview record, and the arguments that have overcome them. See the office action response workflow.

Open AI Studio free →

RCE behavior

Allowance after a Request for Continued Examination versus without one, per year. Use it to judge whether an RCE is worth the cost in front of Examiner Kenyon.

YearRCE rateAllowance w/ RCEAllowance w/oDelta
202211.0%100.0%65.9%+34.1pp
20218.2%71.4%61.8%+9.6pp

Recent outcomes

Free🔒 Case detail for members
App #TitleOutcomeOAsArguments & redline
18/606590Methods for Treating CancerPatented1🔒 View
18/559288Heterocyclic TRPML1 Agonists and Uses ThereofPatented0🔒 View
18/557919Xanthine Oxidase InhibitorPatented0🔒 View
18/311744Process for the Purification of MitragyninePatented1🔒 View
See all 378 applications with full file-wrapper detailOffice action text, attorney arguments, amendments & claim-by-claim track changes
Start free

Art Unit 1625 technology

Heterocyclic compoundsMedicinal chemistryDrug compoundsOrganic synthesisTop CPC C07D · A61K · C07C
About this examiner. John S. Kenyon examines in Art Unit 1625 (Heterocyclic Drug Compounds & Medicinal Chemistry, Tech Center 1600). Working on compound or antibody claims? See Life Sciences in AI Studio.

Frequently asked questions

What is Examiner John S. Kenyon's allowance rate?
Examiner Kenyon's allowance rate is 68.4%, compared with 82.2% across the USPTO and 69.9% in Art Unit 1625 for applications filed in the same years. That rate ranks Examiner Kenyon harder than 75% of examiners.
Is Examiner Kenyon a hard examiner?
Somewhat. Examiner Kenyon ranks harder than 75% of examiners, in the 75th difficulty percentile (hard). Examiner Kenyon has a 68.4% allowance rate versus 82.2% across the USPTO and 69.9% in Art Unit 1625, 0.9 office actions per application versus 1.3, and an RCE rate of 6.6% versus 20.1% across the USPTO, for applications filed in the same years.
Do examiner interviews help with Examiner Kenyon?
In this examiner's record, yes. Decided applications with an interview were allowed more often in both measured years, by 29.1 to 32.6 percentage points. In 2021, 88.9% of decided applications with an interview were allowed, versus 59.8% of those without.
What is Examiner Kenyon's most common rejection?
§112 definiteness & disclosure, issued 134 times in the data. Applicants overcame it 79.0% of the time. Of the 55 winning responses Boundly has classified, 29 amended the claims and argued.
Is an RCE worth filing with Examiner Kenyon?
In this examiner's record, yes. Decided applications with an RCE were allowed more often in both measured years, by 9.6 to 34.1 percentage points. In 2022, 100.0% of decided applications with an RCE were allowed, versus 65.9% of those without one.
How long until the first office action from Examiner Kenyon?
About 778 days on average, versus 624 days across the USPTO for applications filed in the same years.
How do I contact Examiner John S. Kenyon?
Examiner Kenyon can be reached by email at [email protected]. The examiner's direct line is listed at the end of the examiner's office actions.

Put Examiner Kenyon's data to work on your next response.

Full file-wrapper detail, winning arguments, and AI-assisted drafting in one workspace.

Start free
Statistics are computed by Boundly Prosecution Intel from USPTO Patent Center (formerly PAIR) file wrappers for filing years 2021–2026, refreshed regularly. Allowance rate (sometimes called grant rate) is the share of disposed applications that issued as patents. Office actions here are non-final and final rejections, so restriction requirements and allowances are not counted. USPTO benchmarks are weighted to each examiner's mix of filing years, and art-unit benchmarks to the art units and filing years of the examiner's own applications, so they compare like for like. The difficulty percentile ranks examiners, each counted once, so it can point the other way from the USPTO average, which counts applications. See how each number is computed. The year-by-year interview and RCE tables show up to four recent filing years, leaving out the newest one and any year with fewer than ten applications or five decided applications on either side. Historical data is provided for informational purposes only. Past examiner behavior does not guarantee future outcomes, and nothing here is legal advice or a substitute for advice from a licensed patent attorney or agent. Are you John S. Kenyon, or see an error? Request a correction.